公开(公告)号：EP3858339A1

公开(公告)日：2021-08-04

申请号：EP20214642.9

申请日：2012-12-21

申请人： Reprise Pharmaceuticals, Inc.

发明人： FRIESE, Manuel ,  SCHATTLING, Benjamin ,  STEINBACH, Karin ,  FREICHEL, Marc ,  FLOCKERZI, Veit ,  VENNEKENS, Rudi ,  MERKLER, Doron

IPC分类号： A61K31/00 ,  A61K31/05 ,  A61K31/132 ,  A61K31/196 ,  A61K31/198 ,  A61K31/352 ,  A61K31/365 ,  A61K31/4402 ,  A61K31/4453 ,  A61K31/473 ,  A61K31/565 ,  A61K31/566 ,  A61K45/06 ,  A61K31/64 ,  A61P25/00 ,  A61P25/28 ,  G01N33/50 ,  G01N33/68

摘要： The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a neurodegenerative disease, such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis, in a subject. The invention also provides a pharmaceutical composition comprising a TRPM4 inhibitory compound. The invention further relates to in vitro methods for identifying pharmaceutically active compounds that are useful for treating or preventing a neurodegenerative disease.